Respiratory System Drugs Practice Questions

Q: All of the following are expectorants except:

Noscapine. ***Noscapine*** - **Noscapine** is an **antitussive** (cough suppressant) that works by suppressing the **cough reflex** in the brainstem, with no expectorant properties. - It is an **opium alkaloid** derivative but lacks significant analgesic or addictive effects. *Hypertonic saline* - **Hypertonic saline** is used as an **expectorant** to induce sputum production by drawing water into the airways through osmosis, thinning mucus. - It works by irritating the airways, leading to a reflexive increase in mucus secretion and clearance. *Guaifenesin* - **Guaifenesin** is a well-known **expectorant** that works by increasing the volume and reducing the viscosity of respiratory tract secretions. - This helps to facilitate the removal of mucus from the airways by making coughs more productive. *Ammonium chloride* - **Ammonium chloride** acts as a **systemic expectorant** by irritating the bronchial mucosa, which reflexively increases the secretion of respiratory fluids. - It is thought to thin the mucus, making it easier to expel.

Q: Which is the most common side effect of inhaled beclomethasone dipropionate?

Oropharyngeal candidiasis. ***Oropharyngeal candidiasis*** - Inhaled corticosteroids like **beclomethasone dipropionate** can suppress the local immune response in the oral cavity. - This immunosuppression creates an environment conducive to the overgrowth of *Candida albicans*, leading to **thrush**. *Pneumonia* - While inhaled corticosteroids can slightly increase the risk of pneumonia in some populations (e.g., COPD patients), it is **not the most common** side effect. - **Oropharyngeal candidiasis** is much more frequently encountered. *Atrophic rhinitis* - This condition involves inflammation and thinning of the nasal lining, often associated with chronic infections or surgery. - It is **not a typical or common side effect** of inhaled corticosteroids. *Pituitary adrenal suppression* - Systemic absorption of high doses of inhaled corticosteroids can lead to **adrenal suppression**, but this is a **less common and more serious** side effect, usually seen with prolonged high-dose use. - **Oropharyngeal candidiasis** is a local effect and far more prevalent.

Q: Which class of bronchodilators is considered the most effective for managing chronic obstructive pulmonary disease (COPD)?

Anticholinergic agents. ***Anticholinergic agents*** - **Anticholinergic agents** (LAMAs), like tiotropium, are proven most effective for **COPD** management due to their sustained bronchodilation and ability to reduce exacerbations [1], [2]. - They work by blocking the action of **acetylcholine** on muscarinic receptors in the airways, preventing bronchoconstriction [1]. *Beta-adrenergic agents* - **Beta-adrenergic agents** (LABAs) are also effective bronchodilators in COPD, but anticholinergics show a more consistent benefit in reducing **exacerbations** and improving lung function in long-term studies [2]. - While essential for bronchodilation, they primarily target beta-2 receptors, leading to immediate but sometimes less sustained effects compared to **LAMAs**. [2] *Cholinergic agents* - **Cholinergic agents** are typically **bronchoconstrictors** as they stimulate muscarinic receptors, leading to airway smooth muscle contraction. - They are generally contraindicated in asthma and COPD due to their ability to worsen **airway narrowing**. *Alpha-adrenergic agents* - **Alpha-adrenergic agents** primarily affect blood vessels and have minimal direct bronchodilatory effects on the airways. - They are not used as primary bronchodilators for **COPD**; their use might be restricted to systemic effects like decongestion.

Q: Omalizumab is indicated for which of the following conditions?

Bronchial asthma. ***Bronchial asthma*** - Omalizumab is an **anti-IgE antibody** that binds to circulating IgE, preventing it from binding to mast cells and basophils, thus reducing allergic reactions. - It is specifically approved for the treatment of **moderate to severe persistent asthma** in patients over 6 years old whose symptoms are inadequately controlled by inhaled corticosteroids. *Multiple myeloma* - Multiple myeloma is a **plasma cell malignancy** affecting bone marrow, for which omalizumab has no approved indication. - Treatment typically involves **chemotherapy**, proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation. *Psoriasis* - Psoriasis is a **chronic inflammatory skin condition** primarily treated with agents targeting inflammatory pathways such as TNF-alpha, IL-17, or IL-23, not IgE. - Common psoriasis medications include **topical corticosteroids**, phototherapy, and systemic biologics like adalimumab or ustekinumab. *Rheumatoid arthritis* - Rheumatoid arthritis is an **autoimmune disease** causing chronic joint inflammation, primarily treated with DMARDs (disease-modifying antirheumatic drugs) and TNF inhibitors. - **IgE does not play a significant role** in the pathogenesis of rheumatoid arthritis, making omalizumab ineffective for this condition.

Q: Which of the following is an antiasthmatic?

Salbutamol. ***Salbutamol*** - Salbutamol is a **short-acting beta-2 adrenergic agonist** that causes **bronchodilation** by relaxing the smooth muscles of the airways, making it an effective antiasthmatic medication. - It is often used as a **reliever medication** for acute asthma symptoms due to its rapid onset of action. *Histamine* - Histamine is a **mediator of allergic reactions** and inflammation, causing **bronchoconstriction** and increased mucus production, which worsens asthma symptoms. - It works by binding to H1 receptors in the airways, contributing to the pathophysiology of asthma rather than treating it. *Acetylcholine* - Acetylcholine is a **neurotransmitter** that can cause **bronchoconstriction** by stimulating muscarinic receptors in the airway smooth muscle. - While it plays a role in regulating airway tone, it is not used as an antiasthmatic; rather, **anticholinergics** are sometimes used to block its effects. *Serotonin* - Serotonin (5-hydroxytryptamine, 5-HT) can have **bronchoconstrictive effects** in some individuals and contribute to airway hyperresponsiveness, but it is not a direct therapeutic target for asthma. - It is primarily known for its role in the central nervous system and the gastrointestinal tract, and is not classified as an antiasthmatic drug.

Q: In comparison to inhaled adrenergic agonists, the inhaled anticholinergics:

Produce a slower response in bronchial asthma. ***Produce a slower response in bronchial asthma*** - **Inhaled anticholinergics** (e.g., ipratropium, tiotropium) block **muscarinic receptors**, leading to bronchodilation, but their onset of action is generally **slower** (15-30 minutes) compared to the rapid action of **beta-2 adrenergic agonists** (5 minutes). - This slower response makes them less ideal for **acute asthma attacks** where immediate bronchodilation is critical. - Anticholinergics are used as **add-on therapy** in asthma management. *Are more effective in bronchial asthma* - **Inhaled beta-2 adrenergic agonists** (e.g., salbutamol, albuterol) are typically **more effective** and are the **first-line treatment** for acute bronchodilation in asthma due to their rapid onset and potent effect. - **Anticholinergics** are often considered **add-on therapy** for asthma, particularly for patients who have an inadequate response to beta-agonists. *Produce little benefit in chronic obstructive lung disease* - **Inhaled anticholinergics** (e.g., tiotropium, ipratropium) are considered **first-line agents** and provide **significant benefit** in improving lung function and reducing exacerbations in **chronic obstructive pulmonary disease (COPD)**. - Their efficacy in COPD is often **superior** to beta-agonists for long-term maintenance therapy due to the prominent role of cholinergic tone in COPD bronchoconstriction. *Are better suited for control of an acute attack of asthma* - **Short-acting inhaled beta-2 adrenergic agonists** are the **drug of choice** for the rapid relief of acute asthma symptoms due to their quick onset of action. - **Inhaled anticholinergics** like **ipratropium** have a slower onset and are generally used as **adjunctive therapy** or for patients unable to tolerate beta-agonists during acute exacerbations.

Q: Which interleukin is specifically targeted by the monoclonal antibody Reslizumab in the treatment of bronchial asthma?

Interleukin-5. ***Interleukin-5*** - **Reslizumab** is a humanized monoclonal antibody specifically designed to target and inhibit **interleukin-5 (IL-5)** [1]. - By blocking IL-5, Reslizumab reduces the production, survival, and activation of **eosinophils**, which are key inflammatory cells in a subset of severe asthma [1]. *Interleukin-2* - **Interleukin-2 (IL-2)** primarily plays a role in the proliferation and differentiation of **T lymphocytes**, and its blockade is typically associated with immunosuppression. - While important in immune responses, IL-2 is not the specific target of Reslizumab for treating eosinophilic asthma. *Interleukin-3* - **Interleukin-3 (IL-3)** is involved in the growth and differentiation of various **hematopoietic stem cells** and is less directly linked to the pathogenesis of eosinophilic asthma than IL-5. - Medications targeting IL-3 are not used in the treatment of asthma. *Interleukin-4* - **Interleukin-4 (IL-4)** is a crucial cytokine involved in **Th2 immune responses**, promoting IgE production and B-cell activation, but it is not directly targeted by Reslizumab [1]. - Another monoclonal antibody, **Dupilumab**, targets both IL-4 and IL-13 receptors in asthma treatment [1].

Q: Which of the following is not typically used for the immediate treatment of acute asthma?

Salmeterol. ***Salmeterol*** - **Salmeterol** is a **long-acting beta-2 agonist (LABA)**, typically used for **maintenance therapy** in asthma to prevent symptoms, not for immediate relief of an acute attack. - Its **slow onset of action** makes it unsuitable for the rapid bronchodilation required during an acute asthma exacerbation. *Prednisolone* - **Prednisolone** is an **oral corticosteroid** used in acute asthma exacerbations to reduce inflammation and prevent relapse. - While it has a delayed onset of action, it is a crucial component of immediate management to control the underlying inflammation. *Salbutamol* - **Salbutamol** is a **short-acting beta-2 agonist (SABA)**, which is the **first-line treatment** for immediate relief of acute asthma symptoms. - It acts rapidly to **bronchodilate** the airways, improving airflow within minutes. *Ipratropium bromide* - **Ipratropium bromide** is a **short-acting muscarinic antagonist (SAMA)** that can be used in conjunction with SABAs for acute severe asthma. - It provides **additional bronchodilation** by blocking acetylcholine's effects on bronchial smooth muscle.

Q: Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?

Ipratropium (short-acting anticholinergic). ***Ipratropium (short-acting anticholinergic)*** - Ipratropium is a **bronchodilator** that acts as an **anticholinergic** via **M3 muscarinic receptor antagonism** in the airways. - It has **minimal systemic absorption** and produces **no direct cardiac stimulation**, making it the option with the least cardiovascular side effects. - While typically used as an **adjunct to beta-agonists** in acute asthma, it has the most favorable cardiac safety profile among bronchodilators. - Particularly useful in patients with **severe cardiovascular disease** where minimizing cardiac stimulation is crucial. *Salbutamol (short-acting beta-agonist)* - Salbutamol is a **selective beta-2 adrenergic agonist** and the first-line treatment for acute asthma. - Despite beta-2 selectivity, it can have **off-target effects on cardiac beta-1 receptors**, potentially causing tachycardia, palpitations, and increased myocardial oxygen demand. - At therapeutic doses, cardiac effects are usually mild and acceptable even in cardiovascular patients, but more pronounced than ipratropium. *Terbutaline (short-acting beta-agonist)* - Terbutaline is a **beta-2 agonist** with similar cardiac risk profile to salbutamol. - Can cause **tachycardia and arrhythmias** due to non-specific beta-adrenergic activation, particularly at higher doses or in sensitive patients. - Effective for acute bronchodilation but produces more cardiac stimulation than anticholinergics. *Formoterol (long-acting beta-agonist)* - Formoterol is a **long-acting beta-2 agonist (LABA)** with rapid onset but prolonged duration of action. - **Not recommended for acute asthma attacks** as monotherapy; LABAs are maintenance medications. - Has potential for significant **cardiac side effects** including palpitations, tremor, and arrhythmias due to prolonged beta-adrenergic stimulation. - Carries greater cardiovascular risk than short-acting agents due to extended systemic exposure.

Question 1

All of the following are expectorants except:

Accepted Answer

Noscapine

Answer

Guaifenesin

Answer

Ammonium chloride

Answer

Hypertonic saline

Question 2

Which is the most common side effect of inhaled beclomethasone dipropionate?

Accepted Answer

Oropharyngeal candidiasis

Answer

Pneumonia

Answer

Atrophic rhinitis

Answer

Pituitary adrenal suppression

Question 3

Which class of bronchodilators is considered the most effective for managing chronic obstructive pulmonary disease (COPD)?

Accepted Answer

Anticholinergic agents

Answer

Beta-adrenergic agents

Answer

Cholinergic agents

Answer

Alpha-adrenergic agents

Question 4

Omalizumab is indicated for which of the following conditions?

Accepted Answer

Bronchial asthma

Answer

Multiple myeloma

Answer

Psoriasis

Answer

Rheumatoid arthritis

Question 5

Which of the following is an antiasthmatic?

Accepted Answer

Salbutamol

Answer

Histamine

Answer

Acetylcholine

Answer

Serotonin

Question 6

In comparison to inhaled adrenergic agonists, the inhaled anticholinergics:

Accepted Answer

Produce a slower response in bronchial asthma

Answer

Are more effective in bronchial asthma

Answer

Produce little benefit in chronic obstructive lung disease

Answer

Are better suited for control of an acute attack of asthma.

Question 7

Which interleukin is specifically targeted by the monoclonal antibody Reslizumab in the treatment of bronchial asthma?

Accepted Answer

Interleukin-5

Answer

Interleukin-2

Answer

Interleukin-3

Answer

Interleukin-4

Question 8

Which of the following is not typically used for the immediate treatment of acute asthma?

Accepted Answer

Salmeterol

Answer

Prednisolone

Answer

Ipratropium bromide

Answer

Salbutamol

Question 9

Which of the following drugs has the LEAST cardiac side effects when used for treating an acute attack of asthma in a cardiovascular patient?

Accepted Answer

Ipratropium (short-acting anticholinergic)

Answer

Salbutamol (short-acting beta-agonist)

Answer

Terbutaline (short-acting beta-agonist)

Answer

Formoterol (long-acting beta-agonist)

Respiratory System Drugs — MCQs

Respiratory System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?